Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04038359 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin Lymphoma
A Phase 2 study, sponsored by SecuraBio.
- Completed
- Registry status
- Phase 2
- Development phase
- 103
- Enrollment target
NCT04038359 is a Phase 2 study that has completed, run by SecuraBio. The registered enrollment target is 103 participants.
The verdict
NCT04038359, a Phase 2 study, has completed, sponsored by SecuraBio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 103 participants
- Enrollment target
Study Summary
This study examined the effects of predefined 2-week duvelisib dose holidays on tumor responses and safety/tolerability.
Interventions
- DRUG Duvelisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2019-09-24 |
| Est. Completion | 2023-07-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04038359
The ClinicalTrials.gov registry entry for NCT04038359 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SecuraBio, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Duvelisib is the first listed.
NCT04038359 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04038359 about?
NCT04038359 is a clinical study titled "A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin Lymphoma". This study examined the effects of predefined 2-week duvelisib dose holidays on tumor responses and safety/tolerability.
What is the current status of trial NCT04038359?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 103 participants. The study started on 2019-09-24. Estimated completion is 2023-07-24.
What interventions are being tested in trial NCT04038359?
The interventions under investigation include: Duvelisib (DRUG).
Who is sponsoring clinical trial NCT04038359?
This trial is sponsored by SecuraBio, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.